# DKA Transition to Subcutaneous Insulin

Transition from intravenous to subcutaneous insulin only after ketoacidosis has resolved, oral intake is adequate, and basal insulin timing prevents an interruption in insulin activity. Use a structured overlap, meal-linked prandial dosing, and post-transition glucose surveillance to limit rebound hyperglycemia and recurrent DKA.

**Clinical question:** How should clinicians safely transition a patient with resolved diabetic ketoacidosis from intravenous to subcutaneous insulin?

Updated: 2026-09-15T22:04:14.539674+00:00

## What matters in practice
- Do not stop intravenous insulin for glucose control alone; continue it until ketoacidosis has resolved, with dextrose-containing fluid and/or insulin-rate reduction as glucose falls. [20][21]
- For patients not receiving basal insulin during the infusion, administer subcutaneous insulin and maintain IV insulin for at least 1-2 hours to avoid an insulin gap. [14][18][21]
- Coordinate transition with a meal when possible; resume or initiate rapid-acting insulin with meals once DKA has resolved and oral intake is adequate. [7][8][21]
- Continue a patient’s preadmission long-acting insulin during IV insulin when feasible; for newly diagnosed patients, basal insulin initiation of 0.15-0.3 units/kg is described. [21]
- Early basal insulin given with IV insulin can reduce rebound hyperglycemia without an observed increase in hypoglycemia, but potassium surveillance remains essential. [3][17][20]

## Confirm biochemical resolution and clinical readiness

Transition is a treatment change, not simply an IV-line discontinuation.

Continue fixed-rate IV insulin until ketoacidosis has resolved rather than stopping when glucose normalizes. Endotext defines resolution by pH greater than 7.3, bicarbonate at least 18 mmol/L, and plasma ketones below 0.6 mmol/L; anion-gap normalization is also used in transition protocols. [14][21]

Assess oral intake before converting to a standard basal-bolus regimen. Once DKA has resolved and oral intake is adequate, discontinue IV insulin after appropriate subcutaneous coverage and give or resume rapid-acting insulin with meals. If oral intake remains poor, use a variable-rate insulin infusion with glucose-containing solutions rather than an unprotected transition to meal-based subcutaneous insulin. [21]

A falling glucose concentration does not establish DKA resolution. When glucose falls below 250 mg/dL, reduce the IV insulin rate to 0.05 units/kg/hour and continue insulin with a glucose target of about 200 mg/dL while ketoacidosis clears; dextrose-containing fluids permit continued anti-ketogenic insulin delivery. [20][21]
- Before transition, document pH, bicarbonate, serum ketones when available, anion gap, bedside glucose, potassium, and ability to eat. Resolution markers determine whether IV insulin can stop; potassium and glucose determine how safely it can continue. [14][19][21]
- For an intended meal-based transition, arrange administration of rapid-acting insulin before the meal rather than waiting until after food intake. [7][8][21]

*Operational criteria for IV-to-SC insulin transition in DKA. [14][21]*

| Decision point | Action |
| --- | --- |
| Ketoacidosis not resolved | Continue IV insulin; use dextrose-containing fluid and/or lower the infusion rate as glucose falls rather than stopping insulin. [20][21] |
| pH >7.3, bicarbonate ≥18 mmol/L, and plasma ketones <0.6 mmol/L | DKA is resolved by Endotext criteria; proceed to planned SC coverage if the patient can take oral nutrition. [21] |
| Oral intake adequate | Give or resume rapid-acting insulin with meals and establish basal insulin coverage before stopping IV insulin. [7][8][21] |
| Oral intake poor | Use variable-rate IV insulin with glucose solutions instead of a routine meal-based SC transition. [21] |

## Establish basal insulin before removing IV insulin coverage

The central safety task is avoiding a period without effective insulin.

For patients already taking long-acting insulin before admission, continue basal insulin during IV insulin treatment when feasible. This preserves basal coverage and facilitates transition to a basal-bolus regimen once ketoacidosis resolves. [21]

For a newly diagnosed patient, initiate basal insulin at 0.15-0.3 units/kg as part of transition planning. Add rapid-acting insulin with meals only after DKA resolution and adequate oral intake. [21]

If basal insulin was not administered during the IV insulin course, give the planned subcutaneous insulin dose and continue IV insulin for at least 1-2 additional hours. An electronic transition intervention specifically targeted IV insulin discontinuation without long-acting insulin in the prior 2-6 hours and reinforced a minimum 2-hour overlap. [14][18][21]
- Known diabetes: return to the prior home insulin regimen when clinically appropriate, then adjust for inpatient glucose control. [14]
- New diabetes: prescribe a basal regimen before IV discontinuation, then pair it with prandial rapid-acting insulin when meals resume. [21]
- Do not rely on correction-only insulin as the sole bridge after IV insulin is stopped; planned basal coverage is required to prevent an interruption in insulin action. [14][18][21]

*Subcutaneous insulin transition pathways. [14][18][21]*

| Clinical situation | Subcutaneous plan | IV insulin stop timing |
| --- | --- | --- |
| Long-acting insulin used before admission | Continue basal insulin during IV treatment; resume rapid-acting insulin with meals after resolution and adequate intake. [21] | Discontinue after DKA resolution and transition plan is active. [21] |
| No basal insulin given during IV treatment | Administer planned SC insulin, including basal coverage. [14][18][21] | Maintain IV insulin for at least 1-2 hours after SC administration. [14][18][21] |
| Newly diagnosed diabetes | Initiate basal insulin 0.15-0.3 units/kg; add meal-associated rapid-acting insulin when eating. [21] | Use the same 1-2-hour overlap if basal insulin was not already coadministered. [21] |
| Poor oral intake | Use variable-rate IV insulin plus glucose solutions. [21] | Do not convert to a routine meal-based SC regimen until intake is adequate. [21] |

## Consider early basal insulin to simplify transition

Early basal insulin is an adjunct to—not a replacement for—IV insulin during active DKA.

Coadministration of long-acting basal insulin during IV insulin infusion is increasingly used. Trials summarized in a randomized-trial report found that glargine U-100 at 0.15-0.3 units/kg during IV insulin was associated with shorter time to DKA resolution, shorter IV insulin duration, shorter hospital stay, and less rebound hyperglycemia without increased hypoglycemia. [3]

A systematic review and meta-analysis of randomized trials found no evidence that early basal insulin increased hypoglycemia; pooled hypokalemia rates were not significantly different, although a trend toward more hypokalemia was observed. Continue potassium monitoring because hypokalemia occurs in up to 55% of DKA cases. [17]

Early basal insulin is most useful when a predictable transition to basal-bolus therapy is expected or when failure to overlap insulin is a recurrent systems problem. It does not permit premature discontinuation of IV insulin: continue the infusion until biochemical DKA resolution. [17][20][21]
- Early basal option reported in trials: insulin glargine U-100, 0.15-0.3 units/kg subcutaneously during IV insulin infusion. [3]
- For newly diagnosed patients, the same 0.15-0.3 units/kg basal starting range is described in transition guidance. [21]
- Monitor potassium closely during concurrent insulin therapy; insulin-related intracellular electrolyte shifts can produce hypokalemia. [17][19]

*Early basal insulin: practical tradeoff. [3][17][20][21]*

| Potential advantage | Required safeguard |
| --- | --- |
| May reduce rebound hyperglycemia and shorten IV insulin exposure. [3][20] | Do not stop IV insulin until ketoacidosis has resolved. [20][21] |
| Avoids a late transition insulin gap when basal insulin is given during the infusion. [21] | Continue serial potassium assessment; hypokalemia is common during DKA treatment. [17] |
| No increased hypoglycemia signal in pooled randomized-trial data. [17] | Continue frequent bedside glucose monitoring while IV insulin remains active. [19][20] |

## Detect rebound hyperglycemia, hypoglycemia, and recurrent ketosis

The highest-risk errors occur when overlap, meal timing, and IV dextrose are changed simultaneously.

During IV insulin therapy, check bedside glucose hourly and obtain serial basic metabolic testing to follow bicarbonate, anion gap, potassium, magnesium, and phosphate. These measurements identify persistent ketoacidosis and insulin-associated electrolyte shifts before transition. [19][20]

At conversion, explicitly reconcile three orders: long-acting insulin administration, IV insulin stop time, and dextrose-containing fluid discontinuation. A quality-improvement protocol used a mandatory checklist for at least 2 hours of IV/SC overlap and guidance on stopping IV dextrose-containing fluids to reduce post-transition dysglycemia. [18]

Treat post-transition glucose excursions as a possible coverage failure rather than assuming DKA has recurred. Reassess whether basal insulin was administered, whether there was a 1-2-hour overlap, whether prandial insulin matched nutrition, and whether biochemical resolution was documented before the infusion was stopped. [14][18][21]
- Hourly bedside glucose monitoring is standard during active IV insulin infusion. [19][20]
- Hypoglycemia is defined as blood glucose below 70 mg/dL in the cited transition study; correct promptly and reassess insulin and dextrose orders. [19]
- If anion gap, bicarbonate, or ketones worsen after IV insulin discontinuation, restart evaluation for recurrent or incompletely resolved ketoacidosis and restore continuous insulin coverage as indicated. [14][19][21]

*Transition-order checklist and response to abnormal findings. [14][18][19][21]*

| Check | Finding | Next action |
| --- | --- | --- |
| Biochemical status before IV stop | DKA resolution criteria not met. [21] | Continue IV insulin with glucose support as needed; do not complete transition. [20][21] |
| Basal insulin administration | No basal insulin during infusion. [14][18][21] | Give SC insulin and maintain IV insulin for at least 1-2 hours. [14][18][21] |
| Nutrition | Unable to eat reliably. [21] | Use variable-rate IV insulin with glucose solutions. [21] |
| Post-transition glucose | Blood glucose <70 mg/dL. [19] | Treat hypoglycemia promptly and reassess insulin and dextrose orders. [19] |
| Post-transition metabolic panel | Reopening anion gap or worsening bicarbonate/ketones. [14][19][21] | Evaluate for persistent or recurrent ketoacidosis and restore continuous insulin coverage as clinically indicated. [14][19][21] |

## References
1. Diabetic Ketoacidosis Management in Pediatric Populations | Endocrinology | Clinical Sciences | Health sciences | Topics | Nature Index — www.nature.com — https://www.nature.com/nature-index/topics/l4/diabetic-ketoacidosis-management-in-pediatric-populations
2. 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection ... — www.ahajournals.org — https://www.ahajournals.org/doi/pdf/10.1161/CIR.0000000000001453?download=true
3. Early insulin degludec with continuous... : Diabetes, Obesity and Metabolism — journals.lww.com — https://journals.lww.com/00127973-202512000-00019
4. Early versus late initiation of long-acting... : Diabetes, Obesity ... - Ovid — journals.lww.com — https://journals.lww.com/00127973-202605000-00022
5. Estimated Cost-effectiveness of Subcutaneous... : JAMA Network Open — journals.lww.com — https://journals.lww.com/02093599-202209000-00026
6. Effectiveness and safety of early insulin... : Diabetes, Obesity and Metabolism — journals.lww.com — https://journals.lww.com/00127973-202303000-00020
7. Management of Diabetic Ketoacidosis in Children and Adolescents — publications.aap.org — https://publications.aap.org/pediatricsinreview/article/29/12/431/33976/Management-of-Diabetic-Ketoacidosis-in-Children
8. 25: Diabetic Ketoacidosis - AAP Publications — publications.aap.org — https://publications.aap.org/aapbooks/book/676/chapter/8134877/Diabetic-Ketoacidosis
9. Does the Addition of Subcutaneous Basal Insulin Administration ... — www.annemergmed.com — https://www.annemergmed.com/article/S0196-0644(26)00075-2/fulltext
10. Diabetes, Diabetic Ketoacidosis, and Type 2 Diabetes | AAP Books — publications.aap.org — https://publications.aap.org/aapbooks/edited-volume/736/chapter/11706043/Diabetes-Diabetic-Ketoacidosis-and-Type-2-Diabetes
11. Subcutaneous rapid‐acting insulin analogues for diabetic ketoacidosis — www.cochranelibrary.com — https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011281.pub2/full
12. Diabetic Ketoacidosis (Chapter 354) - AAP Publications — publications.aap.org — https://publications.aap.org/pediatriccare/book/348/chapter/5788504/Diabetic-Ketoacidosis-Chapter-354
13. Managing Diabetic Ketoacidosis in Children — www.annemergmed.com — https://www.annemergmed.com/article/S0196-0644(21)00160-8/fulltext
14. [PDF] Clinical Practice Guidelines and Standards of Care of Diabetes ... — extranet.who.int — https://extranet.who.int/ncdccs/Data/sdn_D1_final_Sudan_Diabetes_Guideline_2011%20(2).pdf
15. Pemphigus Vulgaris Complicated by SGLT-2 Inhibitor Associated Euglycemic Diabetic Ketoacidosis | ACS — www.facs.org — https://www.facs.org/for-medical-professionals/news-publications/journals/case-reviews/issues/v5n5/12-stevens-diabetic-ketoacidosis
16. [PDF] Pemphigus Vulgaris Complicated by SGLT-2 Inhibitor Associated ... — www.facs.org — https://www.facs.org/media/ze5da444/12-stevens-diabetic-ketoacidosis.pdf
17. Early subcutaneous basal insulin with intravenous insulin infusion for diabetic ketoacidosis management: A systematic review and meta‐analysis of randomised controlled trials - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC12803681
18. Improving Intravenous and Subcutaneous Insulin Overlap During Treatment of Diabetic Ketoacidosis: A Quality Improvement Project — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC11141259
19. Success of Insulin Infusion Transitions in Moderate to Severe Diabetic Ketoacidosis With Transition Anion Gap of Less Than or Equal to 12 mEq/L Versus Greater Than 12 mEq/L — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC11097940
20. Management of adult diabetic ketoacidosis - PMC - NIH — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC4085289
21. Diabetic Ketoacidosis - Endotext - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK620701
22. Basal insulin for the management of diabetic ketoacidosis — pubmed.ncbi.nlm.nih.gov — https://pubmed.ncbi.nlm.nih.gov/28864157
23. Diabetes and Hypertension Management Manual 15 Mar 2011 — extranet.who.int — https://extranet.who.int/ncdccs/Data/DMA_B6_Diabetes%20and%20Hypertension%20Management%20Manual%2015%20Mar%202011-%20Final2[3].pdf
24. MANAGING DIABETES IN SAINT LUCIA - Extranet Systems — extranet.who.int — https://extranet.who.int/ncdccs/Data/LCA_D1_SLUDiabetes2006.pdf

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.